Brought to you by 
Lilly licenses teplizumab from MacroGenics; deal ends
03 Dec 2015
Executive Summary
Eli Lilly has licensed exclusive worldwide development and commercialization rights to the Phase II/III diabetes candidate teplizumab (MGA031) from MacroGenics (immunotherapies for cancer, autoimmune conditions, and infectious diseases).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly licenses teplizumab from MacroGenics; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice